Irreversible vs Reversible Binding

Introduction

The nature of drug-target binding—reversible or irreversible—fundamentally determines duration of action, dosing strategy, and safety profile. Most drugs bind reversibly, but a growing number of rationally designed covalent (irreversible) inhibitors have proven highly effective, particularly in oncology.

Reversible Binding

Reversible drugs interact with targets through non-covalent forces: hydrogen bonds, van der Waals interactions, electrostatic attraction, and hydrophobic contacts. The drug continuously associates and dissociates, establishing a dynamic equilibrium described by the dissociation constant Kd = koff/kon.

Duration of action depends on the drug's residence time (1/koff) at the target rather than just its affinity. A slow off-rate means prolonged target occupancy even as plasma concentrations fall—explaining why some reversible drugs have effects outlasting their plasma half-life. Tiotropium, for example, has a residence time of ~35 hours at M3 muscarinic receptors despite modest affinity.

Reversible binding is generally considered safer because effects wane predictably as the drug is eliminated from the body.

Irreversible Binding

Irreversible inhibitors form covalent bonds with the target, typically reacting with a nucleophilic amino acid residue (cysteine, serine, threonine, or lysine). The target is permanently inactivated; functional recovery requires de novo synthesis of new protein, which can take hours to days depending on turnover rate.

Many modern irreversible inhibitors use a two-step mechanism: initial reversible binding (recognition) followed by covalent bond formation (inactivation). The kinact/KI ratio quantifies covalent inhibitor potency—kinact is the maximum inactivation rate and KI is the concentration achieving half-maximal rate.

Clinical Implications

Irreversible inhibitors can achieve sustained efficacy at lower plasma concentrations because target recovery depends on protein turnover, not drug exposure. However, off-target covalent modification raises toxicity concerns (e.g., hepatotoxicity), and adverse effects cannot be reversed by simply stopping the drug.

Examples Across Drug Classes

• Aspirin: Irreversibly acetylates COX-1 Ser530; antiplatelet effect lasts 7–10 days
• Omeprazole: Covalently binds H+/K+-ATPase cysteine residues; requires new pump synthesis
• Osimertinib: Covalent EGFR inhibitor targeting Cys797 in T790M-mutant NSCLC
• Metoprolol: Reversible beta-1 antagonist; effect directly tracks plasma levels

Key Takeaways

• Reversible drugs use non-covalent forces and establish dynamic binding equilibrium
• Irreversible drugs form covalent bonds, permanently inactivating the target
• Recovery from irreversible inhibition requires de novo protein synthesis
• Drug residence time (1/koff) can matter more than binding affinity for clinical duration